News in the Life Sciences Industry

LAUSANNE, Switzerland, May 12, 2020 /PRNewswire/ -- Galderma today announced results of DREAM (Dysport Real-world Evaluation and Measured satisfaction study), a clinical study of Dysport®* (abobotulinumtoxinA) for Injection that evaluated patient satisfaction and safety with... Read more ››

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel and BERLIN, May 12, 2020 /PRNewswire/ -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a leading manufacturer of robotic medical devices for individuals with lower limb disabilities, announced the acceptance of the binding offer... Read more ››

BRAUNSCHWEIG, Germany, May 12, 2020 /PRNewswire/ -- YUMAB, a German antibody development company, announced today it has identified fully human monoclonal antibodies with neutralizing activity against patient-derived coronavirus strain SARS-CoV2. This milestone was achieved in collaboration with... Read more ››

- Technology provides more tools to fight difficult-to-treat diseases

Collaboration to Use PixCell's Point-of-Care (POC) HemoScreen™ Platform for Patients to Test from Home Their Chemotherapy Treatment Readiness Supported by Interreg Germany-Denmark

SEOUL, South Korea, May 11, 2020 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) unveiled for the first time the phase 3 clinical data of Fexuprazan, a novel gastroesophageal reflux disease agent at Digestive Disease Week (DDW) 2020. The abstract of Fexuprazan has been rated in the top 10%... Read more ››

SEOUL, South Korea, May 8, 2020 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) unveiled for the first time the phase 3 clinical data of Fexuprazan, a novel gastroesophageal reflux disease agent at Digestive Disease Week (DDW) 2020. The abstract of Fexuprazan has been rated in the top 10%... Read more ››

OSAKA, Japan, and KING OF PRUSSIA, Pa., May 7, 2020 /PRNewswire/ -- The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a plasma-derived hyperimmune globulin therapy for COVID-19, is rapidly building momentum. Its... Read more ››

DUBLIN, May 5, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2020 and updated 2020 financial guidance.